Mythili Kameswaran
Mumbai, MH, India
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Analysis of absorbed dose in radioimmunotherapy with 177Lu-trastuzumab using two different imaging scenarios: a pilot study.
Journal: Nuclear medicine communications
Published: August 18, 2021
Critical APJ receptor residues in extracellular domains that influence effector selectivity.
Journal: The FEBS journal
Published: December 28, 2020
Dose-dependent cell cycle arrest and apoptosis in HER2 breast cancer cells by177Lu-CHX-A"-DTPA-Trastuzumab.
Journal: Journal of cancer research and therapeutics
Published: December 21, 2020
Induction of different cellular arrest and molecular responses in low EGFR expressing A549 and high EGFR expressing A431 tumor cells treated with various doses of 177Lu-Nimotuzumab.
Journal: International journal of radiation biology
Published: July 14, 2020
Comparative In Vitro Cytotoxicity Studies of 177Lu-CHX-A″-DTPA-Trastuzumab and 177Lu-CHX-A″-DTPA-F(ab')2-Trastuzumab in HER2-Positive Cancer Cell Lines.
Journal: Cancer biotherapy & radiopharmaceuticals
Published: March 21, 2020
Preparation and preliminary bioevaluation studies of 68 Ga-NOTA-rituximab fragments as radioimmunoscintigraphic agents for non-Hodgkin lymphoma.
Journal: Journal of labelled compounds & radiopharmaceuticals
Published: June 19, 2019
Synthesis, radiolabeling, and evaluation of gastrin releasing peptide receptor antagonist 68 Ga-HBED-CC-RM26.
Journal: Journal of labelled compounds & radiopharmaceuticals
Published: April 25, 2019
Design, synthesis, and comparative evaluation of 99m Tc(CO)3 -labeled N-terminal and C-terminal modified asparagine-glycine-arginine peptide constructs.
Journal: Journal of peptide science : an official publication of the European Peptide Society
Published: April 16, 2019
Synthesis and preliminary evaluation of 99mTc-Hynic-fragments [F(ab')2 and F(ab')] of Rituximab as radioimmunoscintigraphic agents for patients with Non-Hodgkin's lymphoma.
Journal: Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine
Published: April 06, 2019
Clinical utility of 188Rhenium-hydroxyethylidene-1,1-diphosphonate as a bone pain palliative in multiple malignancies.
Journal: World journal of nuclear medicine
Published: December 04, 2018
Rhenium-188 Hydroxyethane 1,1-Diphosphonic Acid (HEDP) for Bone Pain Palliation Using BARC-HEDP Kits versus Pars-HEDP Kits: A Comparison on Preparation and Performance Aspects at Hospital Radiopharmacy.
Journal: Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India
Published: November 03, 2018
Last Updated: 09/26/2026